Please login to the form below

Not currently logged in
Email:
Password:

ALKS 3831

This page shows the latest ALKS 3831 news and features for those working in and with pharma, biotech and healthcare.

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder ALKS 3831 has cleared an US Food and Drug Administration (FDA) expert advisory committee review. ... ALKS 3831 is a combination of the established oral antipsychotic

Latest news

  • Troubled Alkermes eyes November OK for new antipsychotic Troubled Alkermes eyes November OK for new antipsychotic

    Review begins for potential schizophrenia and bipolar I disorder drug. The FDA has started its review of Alkermes’ experimental antipsychotic for schizophrenia and bipolar I disorder – ALKS 3831 – setting up a ... That left Alkermes more reliant on

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes has been hit hard by the FDA’s rejection of antidepressant candidate ALKS 5461 - citing a lack of evidence that it was clinically effective. ... The setback for ALKS 5461 will leave Alkermes more reliant on a positive read-out for

  • Alkermes depression drug misses targets in phase III Alkermes depression drug misses targets in phase III

    If that occurs, Alkermes said bundling that dataset with a successful phase II trial and the FORWARD-4 results could be enough to build a marketing application for ALKS 56461. ... This is overcome by giving it alongside samidorphan. Samidorphan is also

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics